Real-World Experience of Immunotherapy from India in Recurrent Squamous Cell Carcinoma of Head and Neck Cancer

Background Recurrent metastatic head and neck squamous cell carcinoma (HNSCC) patients carry a poor prognosis and have limited therapeutic options. In the randomized phase-3 trial CheckMate 141, nivolumab showed benefit in overall survival (OS) with manageable toxicity. Nivolumab is available for cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Abbas, Waseem, Gupta, Saurabh, Goel, Vineeta, Rao, Ranga R., Pankaj, Promila, Tripathi, Devashish, Patil, Pratik P., Popli, Swati
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Thieme Medical and Scientific Publishers Private Ltd 2021
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8460346/
https://www.ncbi.nlm.nih.gov/pubmed/34568218
http://dx.doi.org/10.1055/s-0041-1729443

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8460346/
https://www.ncbi.nlm.nih.gov/pubmed/34568218
http://dx.doi.org/10.1055/s-0041-1729443

Ejemplares similares